liquid biopsy market by key players biocept n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Liquid Biopsy Market by key players - Biocept Inc., Myriad Genetics, QIAGEN, Roche, Bio-Rad Laboratories Inc. PowerPoint Presentation
Download Presentation
Liquid Biopsy Market by key players - Biocept Inc., Myriad Genetics, QIAGEN, Roche, Bio-Rad Laboratories Inc.

Loading in 2 Seconds...

play fullscreen
1 / 4

Liquid Biopsy Market by key players - Biocept Inc., Myriad Genetics, QIAGEN, Roche, Bio-Rad Laboratories Inc. - PowerPoint PPT Presentation


  • 5 Views
  • Uploaded on

The Global Liquid Biopsy Market is expected to exceed more than US$ 2 billion by 2022 and will grow at a CAGR of more than 23% in the given forecast period.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Liquid Biopsy Market by key players - Biocept Inc., Myriad Genetics, QIAGEN, Roche, Bio-Rad Laboratories Inc.' - danishsmith01


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
liquid biopsy market by key players biocept

Liquid Biopsy Market by key players - Biocept Inc., Myriad Genetics, QIAGEN, Roche, Bio-Rad LaboratoriesInc.

  • Market Research Engine has published a new report titled as “Liquid Biopsy Market By Type of Cancer Analysis (Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Liver Cancer); By Product and services Analysis (Instruments, Services and Software, Reagents); By Circulation Biomarkers Analysis (Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs), Circulating Tumor DNA (ctDNA)); By End User Analysis (academic & Research Centers, Reference Laboratories, Hospital and Physician Laboratories) and By Regional Analysis – Global Forecast by 2016 - 2022”
  • The Global Liquid Biopsy Market is expected to exceed more than US$ 2 billion by 2022 and will grow at a CAGR of more than 23% in the given forecastperiod.
  • You Can Browse Full Research Report: https://www.marketresearchengine.com/liquid-biopsy-market
  • Liquid biopsy is a minimally invasive technology for detection of molecular biomarkers without the need for high priced or invasive processes. It's an easy and non-invasive alternative to surgical biopsies which allows scientific medical doctors to find out a variety of statistics about a ailment or a tumor through a easy blood pattern. Circulating most cancers cells or lines of the cancer’s RNA or DNA in the blood can provide clues about which remedies are most likely to paintings for that affected person. Circulating nucleic acids are protected with the aid of extracellular micro-vesicles, especially exosomes. A test accomplished on a pattern of blood to search for cancer cells from a tumor that are circulating within the blood or for portions of DNA from tumor cells that are in the blood. A liquid biopsy may be used to assist locate cancer at an early degree. It may additionally be used to help plan treatment or to discover how nicely remedy is working or if cancer has come lowerback.
  • The major driving factors of Global Liquid Biopsy Market are asfollows:
  • Rising new CancerCases
  • TechnicalAdvancements
  • Accessibility of Funding for Liquid BiopsyResearch
  • Initiatives to raise Awareness on LiquidBiopsy
  • The restraining factors of Global Liquid Biopsy Market are asfollows:
  • Low Specificity andSensitivity
  • The Global Liquid Biopsy Market is segmented on the lines of its type of cancer, product and service, circulation biomarkers, end user and regional. Based on type on cancer it covers lung cancer, colorectal cancer, prostate cancer, breast cancer, liver cancer and other cancers. Product and service is classified into instruments, services and software and reagents. Under circulation biomarkers it covers circulating tumor cells, extracellular vesicles, circulating tumor DNA and other biomarkers. End user segment is classifiedinto
academic research centers reference laboratories

academic & research centers, reference laboratories, hospital and physician laboratories and others end user. The Global Liquid Biopsy Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

This reportprovides:

An overview of the global market for Liquid Biopsy and relatedtechnologies.

Analyses of global market trends, with data from 2013, estimates for 2014 and 2015, and projections of compound annual growth rates (CAGRs) through2022.

Identifications of new market opportunities and targeted promotional plans for Global Liquid BiopsyMarket.

Discussion of research and development, and the demand for new products and new applications.

Comprehensive company profiles of major players in theindustry.

  • REPORTSCOPE:
  • The scope of the report includes a detailed study of global and regional markets for Global Liquid Biopsy Market with the reasons given for variations in the growth of the industry in certain regions.
  • The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Biocept Inc. (U.S.), Myriad Genetics (U.S.), QIAGEN (Netherlands), Roche (Switzerland), Bio-Rad Laboratories Inc. (U.S.), Trovagene Inc. (U.S.), Guardant Health, Inc. (U.S.), Janssen Diagnostics, LLC (U.S.), Fraunhofer-Gesellschaft (Germany), and MDxHealth SA (U.S.). Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and currentdevelopments.
  • The Global Liquid Biopsy Markethas been segmented as below: By Type of CancerAnalysis
  • Lung Cancer
  • ColorectalCancer
  • Prostate Cancer
  • BreastCancer
  • LiverCancer
  • OtherCancers
by product and services analysis instruments

By Product and servicesAnalysis

  • Instruments
  • Services andSoftware
  • Reagents
  • By Circulation BiomarkersAnalysis
  • Circulating Tumor Cells(CTCs)
  • Extracellular Vesicles(EVs)
  • Circulating Tumor DNA(ctDNA)
  • Other Biomarkers (Circulating RNA andProtein)
  • By End User Analysis
  • academic & ResearchCenters
  • Reference Laboratories
  • Hospital and PhysicianLaboratories
  • Others EndUser
  • By RegionalAnalysis
  • North America
  • Europe
  • Asia-Pacific
  • Rest of theWorld
  • Request Sample Report:https://www.marketresearchengine.com/liquid-biopsy-market
  • Table of Contents
  • INTRODUCTION
  • ResearchMethodology
  • ExecutiveSummary
  • PremiumInsights
  • MarketOverview
  • IndustryInsights
  • Liquid Biopsy Market, By CancerType
  • Liquid Biopsy Market, By Circulating Biomarker 9 Liquid Biopsy Market, By Products andServices
liquid biopsy market by end user liquid biopsy

Liquid Biopsy Market, By End User

  • Liquid Biopsy Market, By Region 12 CompetitiveLandscape
  • CompanyProfiles
    • Introduction
    • Biocept,Inc.
    • Qiagen
    • F. Hoffmann-La Roche AG
    • Bio-Rad LaboratoriesInc.
    • Myriad Genetics
    • Janssen Diagnostics,LLC.
    • Tr0vageneInc.
    • Guardant HealthInc.
    • Fraunhofer-Gesellschaft
    • MDX HealthSA

MediaContact

Company Name: Market ResearchEngine

Contact Person: JohnBay

Email:john@marketresearchengine.com

Phone: +1-855-984-1862

Country: UnitedStates

Website:https://www.marketresearchengine.com/